- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04064879
The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine
September 26, 2022 updated by: Neurological Associates of West Los Angeles
The present study is being undertaken as a phase I study to determine the safety and feasibility of using adipose derived mesenchymal stem cell preparations (MSC) for treatment of CM.
Intravenous and locally targeted stem cell treatment have already been reported in the context of treating various chronic pain conditions with early evidence of efficacy and a good safety profile.
The treatment of CM is based on the model for treatment with botulinum where superficial facial and cranial injections are utilized.
In addition, stem cells can be given intravenously as well.
Study Overview
Detailed Description
Chronic migraine (CM) is a disabling complex neurological disorder recognized as a complication of migraine in the the International Classification of Headache Disorders.
Patients with CM experience headache on 15 days per month.
CM is associated with significant disability and reduced health-related quality of life.
Approximately 1.3% to 2.4% of the general population suffers from CM, and one in five CM sufferers cannot work because this condition impacts their ability to lead productive lives.
CM is frequently complicated by overuse of acute pain medications.
Some drugs have regulatory approval for migraine prophylaxis; none are approved specifically for CM prophylaxis although recently, botulinum injection has been FDA approved for CM treatment with marginal treatment effects with many patients failing to have complete remission.
The present study is being undertaken as a phase I study to determine the safety and feasibility of using adipose derived mesenchymal stem cell preparations (MSC) for treatment of CM.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Monica, California, United States, 90403
- Neurological Associates of West Los Angeles
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must exhibit symptoms that satisfy criteria of Chronic Migraine (e.g., experiencing headaches at least 15 days per month to a degree that is associated with significant disability and reduced health-related quality of life).
Exclusion Criteria:
- Advanced stages of any terminal illness or active cancer that requires chemotherapy.
- Pregnancy, women who may become pregnant or are breastfeeding.
- Bleeding disorder, untreated.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deployment of AD-SVF
Administration of autologous adipose derived SVF
|
Intravenous, intra-articular, and soft tissue injection delivery of SVF.
Target regions include forehead, temporal, and suboccipital regions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event Reporting
Time Frame: Throughout study duration (Baseline through 36 months)
|
Any participants with adverse events suspected to be related to either SVF deployment or the lipo-harvesting procedure were noted and reported immediately.
|
Throughout study duration (Baseline through 36 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Headache Diary
Time Frame: 2 months
|
Headache pain is scored on a range from 0 'no pain' to 10 'worst pain ever.' Patients reported the number of headaches total per month (each diary has a total possible number of 31 entries).Total score is calculated by adding the sum score of each headache (maximum possible = 310).
Clinical improvement was noted for patients whose scores improved by at least 20%.
|
2 months
|
Headache Impact Test (HIT-6)
Time Frame: 2 months
|
The HIT-6 is a self-report questionnaire consisting of 6 questions, with qualitative answers ranging from "never," "rarely," "sometimes," "very often," and "always" to describe the frequency and impact of headaches on patient lives.
Answers correspond with point values as following: never = 6 points, rarely = 8 points, sometimes = 10 points, very often = 11 points, & always = 13 points.
A total score of 50 or more indicates severe disability related to headaches.
Clinical improvement was noted for patients who reported at least a 20% decrease in their scores from baseline.
|
2 months
|
Headache Diary
Time Frame: 6 months
|
Headache pain is scored on a range from 0 'no pain' to 10 'worst pain ever.' Patients reported the number of headaches total per month (each diary has a total possible number of 31 entries).Total score is calculated by adding the sum score of each headache (maximum possible = 310).
Clinical improvement was noted for patients whose scores improved by at least 20% from baseline.
|
6 months
|
Headache Impact Test (HIT-6)
Time Frame: 6 months
|
The HIT-6 is a self-report questionnaire consisting of 6 questions, with qualitative answers ranging from "never," "rarely," "sometimes," "very often," and "always" to describe the frequency and impact of headaches on patient lives.
Answers correspond with point values as following: never = 6 points, rarely = 8 points, sometimes = 10 points, very often = 11 points, & always = 13 points.
A total score of 50 or more indicates severe disability related to headaches.
Clinical improvement was noted for patients who reported at least a 20% decrease in their scores from baseline.
|
6 months
|
Headache Diary
Time Frame: 1 year
|
Headache pain is scored on a range from 0 'no pain' to 10 'worst pain ever.' Patients reported the number of headaches total per month (each diary has a total possible number of 31 entries).Total score is calculated by adding the sum score of each headache (maximum possible = 310).
Clinical improvement was noted for patients whose scores improved by at least 20% from baseline.
|
1 year
|
Headache Impact Test (HIT-6)
Time Frame: 1 year
|
The HIT-6 is a self-report questionnaire consisting of 6 questions, with qualitative answers ranging from "never," "rarely," "sometimes," "very often," and "always" to describe the frequency and impact of headaches on patient lives.
Answers correspond with point values as following: never = 6 points, rarely = 8 points, sometimes = 10 points, very often = 11 points, & always = 13 points.
A total score of 50 or more indicates severe disability related to headaches.
Clinical improvement was noted for patients who reported at least a 20% decrease in their scores from baseline.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sheldon E Jordan, MD, FAAN, Neurological Associates of West Los Angeles
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160. doi: 10.1111/j.1468-2982.2003.00824.x. No abstract available.
- Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 Jun;26(6):742-6. doi: 10.1111/j.1468-2982.2006.01172.x.
- Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med. 2006 Jan 12;354(2):158-65. doi: 10.1056/NEJMcp042897. No abstract available. Erratum In: N Engl J Med. 2006 Feb 23;354(8):884.
- Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008 Aug 19;71(8):559-66. doi: 10.1212/01.wnl.0000323925.29520.e7.
- Castillo J, Munoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999 Mar;39(3):190-6. doi: 10.1046/j.1526-4610.1999.3903190.x.
- Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998 Jul-Aug;38(7):497-506. doi: 10.1046/j.1526-4610.1998.3807497.x.
- Lanteri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru G, Henry P, Lucas C, Pradalier A, Chazot G, Gaudin AF. Prevalence and description of chronic daily headache in the general population in France. Pain. 2003 Mar;102(1-2):143-9. doi: 10.1016/s0304-3959(02)00348-2.
- Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):428-32. doi: 10.1136/jnnp.2009.192492. Epub 2010 Feb 17.
- Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004 Aug;3(8):475-83. doi: 10.1016/S1474-4422(04)00824-5.
- Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004 Sep 14;63(5):843-7. doi: 10.1212/01.wnl.0000137039.08724.18.
- Lipton RB, Bigal ME. Chronic daily headache: is analgesic overuse a cause or a consequence? Neurology. 2003 Jul 22;61(2):154-5. doi: 10.1212/wnl.61.2.154. No abstract available.
- Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: a response. Headache. 2011 Jun;51(6):1005-8. doi: 10.1111/j.1526-4610.2011.01925.x. Epub 2011 May 17. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 16, 2018
Primary Completion (Anticipated)
August 15, 2023
Study Completion (Anticipated)
August 16, 2023
Study Registration Dates
First Submitted
August 19, 2019
First Submitted That Met QC Criteria
August 20, 2019
First Posted (Actual)
August 22, 2019
Study Record Updates
Last Update Posted (Actual)
September 28, 2022
Last Update Submitted That Met QC Criteria
September 26, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICSS-2018-014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Migraine, Headache
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Assiut UniversityRecruitingChronic Migraine | Chronic Migraine, HeadacheEgypt
-
Kanuni Sultan Suleyman Training and Research HospitalCompleted
-
Milton S. Hershey Medical CenterTerminatedChronic Migraine, HeadacheUnited States
-
University of SaskatchewanSaskatchewan Health Research FoundationNot yet recruiting
-
Universidad Autonoma de MadridCompletedChronic Migraine | Chronic HeadacheSpain
-
MedtronicNeuroCompletedChronic Migraine HeadacheUnited States, Canada, United Kingdom
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
AbbVieActive, not recruitingChronic Migraine | Episodic MigraineUnited States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom
-
AbbVieActive, not recruitingChronic Migraine | Episodic MigraineJapan
Clinical Trials on AD-SVF
-
Wake Forest University Health SciencesNot yet recruitingOsteoarthritisUnited States
-
Ageless Regenerative InstituteWithdrawnErectile DysfunctionUnited States
-
Ageless Regenerative InstituteWithdrawnDiabetes Mellitus Type IIUnited States
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
AntriaCompletedAging | Wrinkles | LipoatrophyUnited States
-
University of AndorraCompletedKnee OsteoarthritisAndorra
-
Institute of Regenerative and Cellular MedicineUnknown
-
Töölö HospitalHelsinki University Central HospitalRecruitingThumb OsteoarthritisFinland
-
Kantonsspital Winterthur KSWNot yet recruitingPerianal Crohn Disease | Perianal Fistula | Rectovaginal Fistula | Anal Fissure | Perianal Fistula Due to Crohn's DiseaseSwitzerland
-
Ageless Regenerative InstituteTerminatedOsteoarthritisUnited States